RESUMEN
BACKGROUND: Novel biomarkers (BMs) are urgently needed for bronchial asthma (BA) with various phenotypes and endotypes. OBJECTIVE: We sought to identify novel BMs reflecting tissue pathology from serum extracellular vesicles (EVs). METHODS: We performed data-independent acquisition of serum EVs from 4 healthy controls, 4 noneosinophilic asthma (NEA) patients, and 4 eosinophilic asthma (EA) patients to identify novel BMs for BA. We confirmed EA-specific BMs via data-independent acquisition validation in 61 BA patients and 23 controls. To further validate these findings, we performed data-independent acquisition for 6 patients with chronic rhinosinusitis without nasal polyps and 7 patients with chronic rhinosinusitis with nasal polyps. RESULTS: We identified 3032 proteins, 23 of which exhibited differential expression in EA. Ingenuity pathway analysis revealed that protein signatures from each phenotype reflected disease characteristics. Validation revealed 5 EA-specific BMs, including galectin-10 (Gal10), eosinophil peroxidase, major basic protein, eosinophil-derived neurotoxin, and arachidonate 15-lipoxygenase. The potential of Gal10 in EVs was superior to that of eosinophils in terms of diagnostic capability and detection of airway obstruction. In rhinosinusitis patients, 1752 and 8413 proteins were identified from EVs and tissues, respectively. Among 11 BMs identified in EVs and tissues from patients with chronic rhinosinusitis with nasal polyps, 5 (including Gal10 and eosinophil peroxidase) showed significant correlations between EVs and tissues. Gal10 release from EVs was implicated in eosinophil extracellular trapped cell death in vitro and in vivo. CONCLUSION: Novel BMs such as Gal10 from serum EVs reflect disease pathophysiology in BA and may represent a new target for liquid biopsy approaches.
Asunto(s)
Asma , Biomarcadores , Vesículas Extracelulares , Galectinas , Sinusitis , Humanos , Asma/sangre , Asma/fisiopatología , Asma/inmunología , Asma/diagnóstico , Vesículas Extracelulares/metabolismo , Femenino , Masculino , Galectinas/sangre , Biomarcadores/sangre , Adulto , Persona de Mediana Edad , Sinusitis/sangre , Sinusitis/inmunología , Rinitis/sangre , Rinitis/inmunología , Rinitis/fisiopatología , Pólipos Nasales/inmunología , Pólipos Nasales/sangre , Eosinófilos/inmunología , Anciano , Enfermedad CrónicaRESUMEN
Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection of patients at risk of PPF, we performed a proteomic analysis of serum extracellular vesicles (EVs). Notably, the identified candidate biomarkers were enriched for lung-derived proteins participating in fibrosis-related pathways. Among them, pulmonary surfactant-associated protein B (SFTPB) in serum EVs could predict ILD progression better than the known biomarkers, serum KL-6 and SP-D, and it was identified as an independent prognostic factor from ILD-gender-age-physiology index. Subsequently, the utility of SFTPB for predicting ILD progression was evaluated further in 2 cohorts using serum EVs and serum, respectively, suggesting that SFTPB in serum EVs but not in serum was helpful. Among SFTPB forms, pro-SFTPB levels were increased in both serum EVs and lungs of patients with PPF compared with those of the control. Consistently, in a mouse model, the levels of pro-SFTPB, primarily originating from alveolar epithelial type 2 cells, were increased similarly in serum EVs and lungs, reflecting pro-fibrotic changes in the lungs, as supported by single-cell RNA sequencing. SFTPB, especially its pro-form, in serum EVs could serve as a biomarker for predicting ILD progression.
Asunto(s)
Biomarcadores , Progresión de la Enfermedad , Vesículas Extracelulares , Fibrosis Pulmonar , Proteína B Asociada a Surfactante Pulmonar , Vesículas Extracelulares/metabolismo , Humanos , Animales , Biomarcadores/sangre , Ratones , Masculino , Femenino , Fibrosis Pulmonar/sangre , Fibrosis Pulmonar/metabolismo , Fibrosis Pulmonar/patología , Proteína B Asociada a Surfactante Pulmonar/sangre , Proteína B Asociada a Surfactante Pulmonar/metabolismo , Persona de Mediana Edad , Anciano , Enfermedades Pulmonares Intersticiales/sangre , Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/patología , Enfermedades Pulmonares Intersticiales/metabolismo , Pulmón/patología , Pulmón/metabolismo , Proteómica/métodos , Modelos Animales de Enfermedad , Pronóstico , Precursores de Proteínas , Proteínas Asociadas a Surfactante PulmonarRESUMEN
In the original version of this article, the given names of all authors were omitted. The complete names were provided below.Takatoshi Enomoto, Akihiro Tamiya, Kinnosuke Matsumoto, Yuichi Adachi, Koji Azuma, Yuji Inagaki, Shunichi Kouno, Yoshihiko Taniguchi, Nobuhiko Saijo, Kyoichi Okishio, Shinji AtagiThe original article has been corrected.
Asunto(s)
Humanos , Antineoplásicos/uso terapéutico , Antineoplásicos/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/terapia , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Estudios Transversales , Sustitución de Medicamentos , Nivolumab/efectos adversos , Nivolumab/uso terapéuticoRESUMEN
Purpose This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC). Patients/methods Medical records of consecutive patients with advanced NSCLC who received nivolumab between December 2015 and December 2018 were reviewed. Clinical outcomes of three groups of eligible patients who received nivolumab as a second-line treatment after PD were compared based on Response Evaluation Criteria in Solid Tumors v1.1. We conducted subgroup analyses in patients with and without new lesions at first PD. Results Twenty-eight patients continued nivolumab treatment beyond PD (TBP). Post PD, 46 patients switched to other anti-cancer treatment (OAT), and 21 received no further anti-cancer treatment (NAT). There were no significant differences in overall survival (OS) or survival post progression (SPP) between TBP and OAT groups (OS: 15.6 vs. 13.4 months, P = .40, SPP: 12.2 vs. 9.3 months, P = .42). Subgroup analyses indicated that among patients without new lesions at first PD, SPP was longer in the TBP than in the OAT groups (12.6 vs. 9.3 months, P = .22, HR: 0.64; 95% CI 0.31‒1.31). The frequency of immune-related adverse events leading to discontinuation during nivolumab beyond PD was equivalent to that for pre-PD (10.7 vs. 12.6%). Conclusions No significant benefits were associated with continuation of nivolumab for advanced NSCLC patients. Continuation of nivolumab beyond PD could be a more useful option in patients without new lesions at first PD. Treatment-related toxicities require attention during nivolumab treatment not only before PD but also beyond PD (AU)